产后硫酸镁预防子痫的用药时长:系统综述与Meta分析
该系统综述与Meta分析检索MEDLINE、EMBASE、CINAHL、Cochrane系统综述数据库及ClinicalTrials.gov至2020年1月,纳入10项随机对照试验,比较产后不同时点硫酸镁用药时长。结果显示产后硫酸镁短疗程(12小时或更短)与24小时方案相比未增加子痫风险(RD -0.01,95%CI -0.02至0.01,I² 70%)。作者认为短疗程不增加子痫性抽搐风险,但数据检验效能不足,尚不能得出确切结论。
要点
- 产后硫酸镁短疗程(≤12小时)与24小时方案相比,子痫风险无显著差异(RD -0.01,95%CI -0.02至0.01)。
- 子痫前期亚组(RD 0,95%CI -0.01至0.01,I² 0%)与子痫亚组(RD -0.04,95%CI -0.14至0.07,I² 87%)均未显示短疗程增加子痫风险。
- 短疗程组面部潮红、导尿管留置时间、下床活动时间和住院时间均减少。
核心结论
- 该系统综述与Meta分析提示产后硫酸镁短疗程不增加子痫性抽搐风险,但数据检验效能不足,尚不能得出确切结论。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE、CINAHL、Cochrane系统综述数据库及ClinicalTrials.gov自建库至2020年1月,限英文人类随机对照试验。
- 共筛选3629篇文章,最终纳入10项研究,纳入标准为比较子痫前期或子痫产妇产后硫酸镁两个不同时点的研究。
- 由两名作者独立审阅研究,使用RevMan软件计算分类结局的风险差(RD)和连续结局的均数差。
主要发现
- 产后硫酸镁短疗程(12小时或更短)与24小时方案相比,子痫风险无显著差异(RD -0.01,95%CI -0.02至0.01,I² 70%)。
- 随机分配子痫前期产妇的研究中,短疗程未显示子痫风险增加(RD 0,95%CI -0.01至0.01,I² 0%)。
- 随机分配子痫产妇的试验中,短疗程未显示子痫风险增加(RD -0.04,95%CI -0.14至0.07,I² 87%)。
- 次要结局包括面部潮红、导尿管留置时间、下床活动时间和住院时间,短疗程硫酸镁均减少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 数据检验效能不足,尚不能得出确切结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the optimal duration of postpartum magnesium sulphate to prevent eclampsia. DATA SOURCES: MEDLINE, EMBASE, CINAHL, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov databases were searched from inception until January 2020 and limited to English-language human randomized controlled trials. Search strategy included the key works "eclampsia," "magnesium sulphate," and "postpartum." METHODS OF STUDY SELECTION: Title, abstract, and full-text review was performed using Covidence data-management software. Of the 3,629 articles screened, 10 studies were included in the final review. Studies were included if they compared two different time points of magnesium sulphate postpartum in women with either preeclampsia or eclampsia. TABULATION, INTEGRATION AND RESULTS: Two authors reviewed studies independently. RevMan software was used to calculate risk difference (RD) for categorical outcomes and mean difference for continuous outcomes. Shorter duration of magnesium sulphate (12 hours or less) was not associated with increased risk of eclampsia compared with 24-hour postpartum regimens (RD -0.01, 95% CI -0.02 to 0.01, I2 70%). Studies randomizing women with preeclampsia did not show increased risk of eclampsia with shorter regimens (RD 0, 95% CI -0.01 to 0.01, I2 0%), nor did trials randomizing those with eclampsia (RD -0.04, 95% CI -0.14 to 0.07, I2 87%). Secondary outcomes, including flushing, duration of Foley catheter insertion, time to ambulation, and duration of hospital stay, were all reduced with shorter-duration magnesium sulphate. CONCLUSION: This systematic review and meta-analysis suggests that a shorter duration of postpartum magnesium sulphate does not increase the risk for eclamptic seizure; however, data remain underpowered to render firm conclusions. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42020182432.
引用
- Okonkwo M, Nash CM. Duration of Postpartum Magnesium Sulphate for the Prevention of Eclampsia: A Systematic Review and Meta-analysis. Obstet Gynecol. 2022. PMID: 35271534. doi:10.1097/AOG.0000000000004720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。